Jorga K - Search Results

1

A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry.

Graham RA, Lum BL, Morrison G, Chang I, Jorga K, Dean B, Shin YG, Yue Q, Mulder T, Malhi V, Xie M, Low JA, Hop CE. Graham RA, et al. Among authors: jorga k. Drug Metab Dispos. 2011 Aug;39(8):1460-7. doi: 10.1124/dmd.111.039339. Epub 2011 May 20. Drug Metab Dispos. 2011. PMID: 21602311 Clinical Trial.

2

Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding.

Graham RA, Lum BL, Cheeti S, Jin JY, Jorga K, Von Hoff DD, Rudin CM, Reddy JC, Low JA, Lorusso PM. Graham RA, et al. Among authors: jorga k. Clin Cancer Res. 2011 Apr 15;17(8):2512-20. doi: 10.1158/1078-0432.CCR-10-2736. Epub 2011 Feb 7. Clin Cancer Res. 2011. PMID: 21300760 Free PMC article. Clinical Trial.

3

A guide to rational dosing of monoclonal antibodies.

Bai S, Jorga K, Xin Y, Jin D, Zheng Y, Damico-Beyer LA, Gupta M, Tang M, Allison DE, Lu D, Zhang Y, Joshi A, Dresser MJ. Bai S, et al. Among authors: jorga k. Clin Pharmacokinet. 2012 Feb 1;51(2):119-35. doi: 10.2165/11596370-000000000-00000. Clin Pharmacokinet. 2012. PMID: 22257150

4

Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase.

Jorga K, Fotteler B, Heizmann P, Gasser R. Jorga K, et al. Br J Clin Pharmacol. 1999 Oct;48(4):513-20. doi: 10.1046/j.1365-2125.1999.00036.x. Br J Clin Pharmacol. 1999. PMID: 10583021 Free PMC article. Clinical Trial.

5

Model-informed drug development of voxelotor in sickle cell disease: Population pharmacokinetics in whole blood and plasma.

Savic RM, Green ML, Jorga K, Zager M, Washington CB. Savic RM, et al. Among authors: jorga k. CPT Pharmacometrics Syst Pharmacol. 2022 Jun;11(6):687-697. doi: 10.1002/psp4.12731. Epub 2022 Apr 21. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 35447014 Free PMC article.

6

Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects.

Dingemanse J, Jorga K, Zürcher G, Fotteler B, Sedek G, Nielsen T, van Brummelen P. Dingemanse J, et al. Among authors: jorga k. Eur J Clin Pharmacol. 1996;50(1-2):47-55. doi: 10.1007/s002280050068. Eur J Clin Pharmacol. 1996. PMID: 8739811 Clinical Trial.

7

The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations.

Jorga K, Fotteler B, Schmitt M, Nielsen T, Zürcher G, Aitken J. Jorga K, et al. Eur Neurol. 1997;38(1):59-67. doi: 10.1159/000112904. Eur Neurol. 1997. PMID: 9252801 Clinical Trial.

8

The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation.

Jorga K, Fotteler B, Sedek G, Nielsen T, Aitken J. Jorga K, et al. J Neurol. 1998 Apr;245(4):223-30. doi: 10.1007/s004150050209. J Neurol. 1998. PMID: 9591224 Clinical Trial.

9

Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies.

Jorga K, Fotteler B, Banken L, Snell P, Steimer JL. Jorga K, et al. Br J Clin Pharmacol. 2000 Jan;49(1):39-48. doi: 10.1046/j.1365-2125.2000.00113.x. Br J Clin Pharmacol. 2000. PMID: 10606836 Free PMC article. Clinical Trial.

10

Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone.

Jorga K, Banken L, Fotteler B, Snell P, Steimer JL. Jorga K, et al. Clin Pharmacol Ther. 2000 Jun;67(6):610-20. doi: 10.1067/mcp.2000.106795. Clin Pharmacol Ther. 2000. PMID: 10872643

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

43 results

Search Page

Filters